C. D. Bloomfield

16.7k total citations · 3 hit papers
52 papers, 11.8k citations indexed

About

C. D. Bloomfield is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Pathology and Forensic Medicine. According to data from OpenAlex, C. D. Bloomfield has authored 52 papers receiving a total of 11.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 24 papers in Public Health, Environmental and Occupational Health and 14 papers in Pathology and Forensic Medicine. Recurrent topics in C. D. Bloomfield's work include Acute Myeloid Leukemia Research (27 papers), Acute Lymphoblastic Leukemia research (24 papers) and Lymphoma Diagnosis and Treatment (12 papers). C. D. Bloomfield is often cited by papers focused on Acute Myeloid Leukemia Research (27 papers), Acute Lymphoblastic Leukemia research (24 papers) and Lymphoma Diagnosis and Treatment (12 papers). C. D. Bloomfield collaborates with scholars based in United States, Germany and United Kingdom. C. D. Bloomfield's co-authors include M. A. Caligiuri, Eric S. Lander, Jill P. Mesirov, Donna K. Slonim, C. Huard, James R. Downing, Pablo Tamayo, Hilary A. Coller, Mignon L. Loh and Michelle Gaasenbeek and has published in prestigious journals such as Science, Journal of Clinical Oncology and Cancer.

In The Last Decade

C. D. Bloomfield

51 papers receiving 11.2k citations

Hit Papers

Molecular Classification of Cancer: Class Discovery and C... 1990 2026 2002 2014 1999 1999 1990 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
    1999 8.0k citations M. A. Caligiuri, C. D. Bloomfield et al. profile →
  2. The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues
    1999 649 citations Nancy L. Harris, Elaine S. Jaffe et al. Annals of Oncology profile →
  3. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
    1990 617 citations Bruce D. Cheson, Peter A. Cassileth et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. D. Bloomfield United States 25 7.5k 2.5k 1.8k 1.2k 1.2k 52 11.8k
M. A. Caligiuri United States 16 7.1k 0.9× 1.5k 0.6× 1.8k 1.0× 651 0.5× 567 0.5× 27 10.0k
Hilary A. Coller United States 43 13.4k 1.8× 980 0.4× 1.8k 1.0× 1.7k 1.4× 388 0.3× 86 18.1k
Mignon L. Loh United States 57 10.1k 1.3× 5.5k 2.2× 1.8k 1.0× 3.1k 2.5× 6.5k 5.5× 317 19.7k
Michelle Gaasenbeek United Kingdom 8 7.5k 1.0× 427 0.2× 2.1k 1.2× 862 0.7× 291 0.2× 10 10.2k
Andrew P. Weng Canada 32 5.7k 0.8× 1.4k 0.5× 350 0.2× 1.8k 1.5× 1.3k 1.1× 100 9.0k
Satoru Miyano Japan 58 10.5k 1.4× 814 0.3× 1.3k 0.7× 1.3k 1.0× 260 0.2× 523 15.5k
Igor Jurišica Canada 64 10.1k 1.4× 953 0.4× 755 0.4× 2.3k 1.9× 357 0.3× 286 15.9k
Frank Berthold Germany 60 7.9k 1.1× 486 0.2× 605 0.3× 2.9k 2.3× 587 0.5× 320 16.4k
Donna K. Slonim United States 27 10.5k 1.4× 418 0.2× 2.4k 1.4× 721 0.6× 368 0.3× 68 13.8k
Andrea Califano United States 64 12.5k 1.7× 574 0.2× 444 0.2× 3.0k 2.4× 451 0.4× 235 18.7k

Countries citing papers authored by C. D. Bloomfield

Since Specialization
Citations

This map shows the geographic impact of C. D. Bloomfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. D. Bloomfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. D. Bloomfield more than expected).

Fields of papers citing papers by C. D. Bloomfield

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. D. Bloomfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. D. Bloomfield. The network helps show where C. D. Bloomfield may publish in the future.

Co-authorship network of co-authors of C. D. Bloomfield

This figure shows the co-authorship network connecting the top 25 collaborators of C. D. Bloomfield. A scholar is included among the top collaborators of C. D. Bloomfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. D. Bloomfield. C. D. Bloomfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luskin, Marlise R., Jun Yin, Gerard Lozanski, et al.. (2025). Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study. Cancer. 131(4). e35750–e35750. 2 indexed citations
2.
Niederwieser, Christian, Deedra Nicolet, Andrew J. Carroll, et al.. (2016). Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). Haematologica. 101(12). 1516–1523. 13 indexed citations
3.
4.
5.
6.
Marcucci, Guido, Michael A. Caligiuri, & C. D. Bloomfield. (2000). Molecular and Clinical Advances in Core Binding Factor Primary Acute Myeloid Leukemia: A Paradigm for Translational Research in Malignant Hematology. Cancer Investigation. 18(8). 768–780. 38 indexed citations
7.
Harris, Nancy L., Elaine S. Jaffe, J Diébold, et al.. (1999). The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues. Annals of Oncology. 10(12). 1419–1432. 649 indexed citations breakdown →
8.
Heinonen, Kristiina, Krzysztof Mrózek, David Lawrence, et al.. (1998). Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study. British Journal of Haematology. 101(3). 513–520. 21 indexed citations
9.
Byrd, John C., R B Weiss, David Lawrence, et al.. (1997). Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.. Journal of Clinical Oncology. 15(2). 466–475. 180 indexed citations
10.
Mrózek, Krzysztof, Kati Heinonen, Albert de la Chapelle, & C. D. Bloomfield. (1997). Clinical significance of cytogenetics in acute myeloid leukemia.. PubMed. 24(1). 17–31. 202 indexed citations
11.
Bloomfield, C. D., Masaharu Sakurai, Giuliana Alimena, et al.. (1997). Long-term survival of patients with acute myeloid leukemia. Cancer. 80(S11). 2191–2198. 102 indexed citations
12.
Stock, Wendy, Carol A. Westbrook, B. Peterson, et al.. (1997). Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study.. Journal of Clinical Oncology. 15(1). 26–36. 26 indexed citations
13.
Caligiuri, M. A., Matthew P. Strout, Steven A. Schichman, et al.. (1996). Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11.. PubMed. 56(6). 1418–25. 143 indexed citations
14.
Kanost, Michael R., Frederick R. Davey, B. Peterson, et al.. (1995). Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B.. PubMed. 9(7). 1116–20. 28 indexed citations
15.
Baer, Maria R. & C. D. Bloomfield. (1991). The Clinical Significance of Biological Characteristics of the Cells in Acute Myeloid Leukemia. Annual Review of Medicine. 42(1). 381–389. 4 indexed citations
16.
Cheson, Bruce D., Peter A. Cassileth, David R. Head, et al.. (1990). Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.. Journal of Clinical Oncology. 8(5). 813–819. 617 indexed citations breakdown →
17.
Arthur, D, Roland Berger, Harvey M. Golomb, et al.. (1989). The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genetics and Cytogenetics. 40(2). 203–216. 147 indexed citations
18.
Secker‐Walker, Lorna M., Giuliana Alimena, C. D. Bloomfield, et al.. (1989). Cytogenetic studies of 21 patients with acute lymphoblastic leukemia in relapse. Cancer Genetics and Cytogenetics. 40(2). 163–169. 19 indexed citations
19.
Peterson, B. A., et al.. (1983). Patterns of relapse following chemotherapy in non-Hodgkin's lymphoma. 2. 137–144. 1 indexed citations
20.
Peterson, B. A., C. D. Bloomfield, Athanasios Theologides, & B. J. Kennedy. (1981). Daunorubicin-prednisone in the treatment of acute nonlymphocytic leukemia.. PubMed. 65 Suppl 4. 29–33. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. A. Caligiuri Breakdown of academic impact, for papers by Hilary A. Coller Breakdown of academic impact, for papers by Mignon L. Loh Breakdown of academic impact, for papers by Michelle Gaasenbeek Breakdown of academic impact, for papers by Andrew P. Weng Breakdown of academic impact, for papers by Satoru Miyano Breakdown of academic impact, for papers by Igor Jurišica Breakdown of academic impact, for papers by Frank Berthold Breakdown of academic impact, for papers by Donna K. Slonim Breakdown of academic impact, for papers by Andrea Califano
Rankless by CCL
2026